Insights on hematopoietic cell kinase: An oncogenic player in human cancer.

Hematopoietic cell kinase (Hck) is a member of the Src family and is expressed in hematopoietic cells. By regulating multiple signaling pathways, HCK can interact with multiple receptors to regulate signaling events involved in cell adhesion, proliferation, migration, invasion, apoptosis, and angiogenesis. However, aberrant expression of Hck in various hematopoietic cells and solid tumors plays a crucial role in tumor-related properties, including cell proliferation and epithelial-mesenchymal transition. In addition, Hck signaling regulates the function of immune cells such as macrophages, contributing to an immunosuppressive tumor microenvironment. The clinical success of various kinase inhibitors targeting the Src kinase family has validated the efficacy of targeting Src, and therapies with highly selective Hck kinase inhibitors are in clinical trials. This article reviews Hck inhibition as an emerging cancer treatment strategy, focusing on the expressions and functions of Hck in tumors and its impact on the tumor microenvironment. It also explores preclinical and clinical pharmacological strategies for Hck targeting to shed light on Hck-targeted tumor therapy. Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Citation

Shuyan Luo, Shaonan Du, Mei Tao, Jingyuan Cao, Peng Cheng. Insights on hematopoietic cell kinase: An oncogenic player in human cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Apr;160:114339

Mesh Tags

Substances

PMID: 36736283

search → result